 | Epizyme Inc (NASDAQ:EPZM) Expected to Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - September 21 at 8:07 PM |
| Epizyme Inc (NASDAQ:EPZM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 12 at 5:38 PM |
 | Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
finance.yahoo.com - September 8 at 11:08 AM |
| Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - September 8 at 11:08 AM |
| Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth - Yahoo Finance
finance.yahoo.com - September 5 at 1:57 PM |
 | Where Will Epizyme Be in 1 Year? - Motley Fool
www.fool.com - September 5 at 1:57 PM |
| Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team - Yahoo Finance
finance.yahoo.com - September 4 at 10:26 AM |
 | Epizyme (EPZM) Announces Grant Bogle and Victoria Richon, Ph.D to Board; Beth Seidenberg, MD to Step Down - StreetInsider.com
www.streetinsider.com - September 4 at 10:26 AM |
| Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth
finance.yahoo.com - September 4 at 10:26 AM |
| $5.50 Million in Sales Expected for Epizyme Inc (NASDAQ:EPZM) This Quarter
www.americanbankingnews.com - August 31 at 1:17 AM |
| Epizyme to Participate in Upcoming September Conferences - Yahoo Finance
finance.yahoo.com - August 30 at 7:58 PM |
| Epizyme to Participate in Upcoming September Conferences
finance.yahoo.com - August 29 at 11:41 AM |
| How Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay? - Yahoo Finance
finance.yahoo.com - August 16 at 7:55 PM |
| How Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay?
finance.yahoo.com - August 16 at 7:55 PM |
| Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat - Yahoo Finance
finance.yahoo.com - August 15 at 11:44 AM |
 | Epizyme's NDA Filing Acceptance Moves It Forward Toward New Territory - Seeking Alpha
seekingalpha.com - August 13 at 1:23 AM |
| Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates - Yahoo Finance
finance.yahoo.com - August 12 at 12:35 PM |
| Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
finance.yahoo.com - August 10 at 11:18 AM |
| Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates - Yahoo Finance
finance.yahoo.com - August 9 at 8:05 AM |
 | Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 - Nasdaq
www.nasdaq.com - August 9 at 8:05 AM |
| Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates - Nasdaq
www.nasdaq.com - August 9 at 8:05 AM |
| Form 10-Q Epizyme, Inc. For: Jun 30 - StreetInsider.com
www.streetinsider.com - August 9 at 8:05 AM |
| Epizyme Reports Business Progress and Second Quarter 2019 Results - Yahoo Finance
finance.yahoo.com - August 9 at 8:05 AM |
| Epizyme Reports Business Progress and Second Quarter 2019 Results
finance.yahoo.com - August 9 at 8:05 AM |
| Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference - Yahoo Finance
finance.yahoo.com - August 6 at 10:26 AM |
| Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference
finance.yahoo.com - August 6 at 10:26 AM |
| Unum Therapeutics Announces New Appointments to its Board of Directors - Yahoo Finance
finance.yahoo.com - July 29 at 11:30 PM |
 | Unum Therapeutics Announces New Appointments to its Board of Directors - GlobeNewswire
www.globenewswire.com - July 29 at 12:12 PM |
| Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
finance.yahoo.com - July 26 at 1:06 AM |
| Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma - Yahoo Finance
finance.yahoo.com - July 26 at 1:06 AM |
| Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 26 at 1:06 AM |
| Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
finance.yahoo.com - July 25 at 6:34 AM |
| New finance chief at Epizyme - Seeking Alpha
seekingalpha.com - July 22 at 9:06 AM |
| Epizyme: A Promising Long-Term Pick For The Healthcare Investor - Seeking Alpha
seekingalpha.com - July 20 at 10:01 AM |
| Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors - GlobeNewswire
www.globenewswire.com - July 17 at 6:09 PM |
 | How being a female tech founder prepared this CEO to fight the medical system when she got cancer - CNBC
www.cnbc.com - July 13 at 5:23 PM |
| Here's Why Epizyme Rose 103.7% in the First Half of 2019 - The Motley Fool
www.fool.com - July 13 at 5:23 PM |
| Here's Why Epizyme Rose 103.7% in the First Half of 2019
finance.yahoo.com - July 12 at 6:29 PM |
| Epizyme Announces Positive Interim Data on Lead Candidate - Yahoo Finance
finance.yahoo.com - June 25 at 11:16 AM |
| Updated Epizyme data from tazemetostat Phase 2 trial 'positive' - Seeking Alpha
seekingalpha.com - June 21 at 6:57 PM |
| Epizyme (EPZM) Announces Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory FL - StreetInsider.com
www.streetinsider.com - June 21 at 11:08 AM |
| Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma
finance.yahoo.com - June 21 at 11:08 AM |
| Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data - Yahoo Finance
finance.yahoo.com - June 12 at 11:25 AM |
| Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? - Nasdaq
www.nasdaq.com - June 6 at 6:36 PM |
| Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? - Yahoo Finance
finance.yahoo.com - June 5 at 6:36 PM |
| Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?
finance.yahoo.com - June 5 at 6:36 PM |
| Epizyme (EPZM) Presents Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at ASCO 2019 Meetings - StreetInsider.com
www.streetinsider.com - June 3 at 8:45 AM |
| Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
finance.yahoo.com - June 3 at 8:45 AM |
 | Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition - Boston Business Journal
www.bizjournals.com - June 1 at 8:52 AM |
| Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure - Yahoo Finance
finance.yahoo.com - May 31 at 6:32 PM |
